Paul Miller

Dr. Paul Miller

orcid

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 June 2014 in Nature
Verified
Journal Article
Open access
PDF file
PMPaul Miller
Paul Miller
AAA. Radu Aricescu
A. Radu Aricescu
Type-A γ-aminobutyric acid receptors (GABAARs) are the principal mediators of rapid inhibitory synaptic transmission in the human brain. A decline in GABAAR signalling triggers hyperactive neurological disorders such as insomnia, anxiety and epilepsy. Here we present the first three-dimensional structure of a GABAAR, the human β3 homopentamer, at 3 Å resolution. This structure reveals architectural elements unique to eukaryotic Cys-loop receptors, explains the mechanistic consequences of multiple human disease mutations and shows an unexpected structural role for a conserved N-linked glycan. The receptor was crystallized bound to a previously unknown agonist, benzamidine, opening a new avenue for the rational design of GABAAR modulators. The channel region forms a closed gate at the base of the pore, representative of a desensitized state. These results offer new insights into the signalling mechanisms of pentameric ligand-gated ion channels and enhance current understanding of GABAergic neurotransmission.

22 December 2005 in Chemical Reviews
Verified
Journal Article
Closed access
DNDavid M. Noll
David M. Noll
TMTracey McGregor Mason
Tracey McGregor Mason
PMPaul Miller
Paul Miller

20 July 2016 in Nature
Verified
Journal Article
Open access
PDF file
EBEamon F. X. Byrne
Eamon F. X. Byrne
RSRia Sircar
Ria Sircar
PMPaul Miller
Paul Miller
GHGeorge Hedger
George Hedger
GLGiovanni Luchetti
Giovanni Luchetti
CSChristian Siebold
Christian Siebold
Structural studies show that the activity of the G-protein-coupled receptor Smoothened is modulated by ligand-regulated interactions between its extracellular and transmembrane domains. Developmental signals of the Hedgehog (Hh) and Wnt families are transduced across the membrane by Frizzled-class G-protein-coupled receptors (GPCRs) composed of both a heptahelical transmembrane domain (TMD) and an extracellular cysteine-rich domain (CRD). How the large extracellular domains of GPCRs regulate signalling by the TMD is unknown. We present crystal structures of the Hh signal transducer and oncoprotein Smoothened, a GPCR that contains two distinct ligand-binding sites: one in its TMD and one in the CRD. The CRD is stacked atop the TMD, separated by an intervening wedge-like linker domain. Structure-guided mutations show that the interface between the CRD, linker domain and TMD stabilizes the inactive state of Smoothened. Unexpectedly, we find a cholesterol molecule bound to Smoothened in the CRD binding site. Mutations predicted to prevent cholesterol binding impair the ability of Smoothened to transmit native Hh signals. Binding of a clinically used antagonist, vismodegib, to the TMD induces a conformational change that is propagated to the CRD, resulting in loss of cholesterol from the CRD–linker domain–TMD interface. Our results clarify the structural mechanism by which the activity of a GPCR is controlled by ligand-regulated interactions between its extracellular and transmembrane domains. Smoothened (SMO) is a G-protein-coupled receptor that transduces Hedgehog (Hh) signals across the membrane in all animals. Despite being a key developmental regulator, oncoprotein and drug target in oncology, the mechanism by which SMO is activated has remained unknown. These authors solve the 3.2 Å crystal structure of SMO containing its extracellular cysteine-rich (CRD), linker and heptahelical G-protein-coupled receptor (TMD) domains. Surprisingly, a cholesterol molecule was bound to SMO in the CRD binding site. Mutations predicted to prevent cholesterol binding impair the ability of SMO to transmit native Hh signals. Binding of the potent antagonist and anti-cancer drug vismodegib leads to a number of conformational changes and the loss of cholesterol from the CRD–linker domain–TMD interface.

1 April 2010 in Trends in Pharmacological Sciences
Verified
Journal Article
Closed access
PMPaul Miller
Paul Miller
TSTrevor G. Smart
Trevor G. Smart

1 October 2004 in The Neuroscientist
Verified
Journal Article
Closed access
TSTrevor G. Smart
Trevor G. Smart
AHAlastair M. Hosie
Alastair M. Hosie
PMPaul Miller
Paul Miller
The role of Zn2+ in the CNS has remained enigmatic for several decades. This divalent cation is accumulated by specific neurons into synaptic vesicles and can be released by stimulation in a Ca2+-dependent manner. Using Zn2+ fluorophores, radiolabeled Zn2+, and selective chelators, the location of this ion and its release pattern have been established across the brain. Given the distribution and possible release under physiological conditions, Zn2+ has the potential to act as a modulator of both excitatory and inhibitory neurotransmission. Excitatory N-methyl-D-aspartate (NMDA) receptors are directly inhibited by Zn2+, whereas non-NMDA receptors appear relatively unaffected. In contrast, inhibitory transmission mediated via GABAAreceptors can be potentiated via a presynaptic mechanism, influencing transmitter release; however, although some tonic GABAergic inhibition may be suppressed by Zn2+, most synaptic GABA receptors are unlikely to be modulated directly by this cation. In the spinal cord, glycinergic transmission may also be affected by Zn2+ causing potentiation. Recently, the penetration of synaptically released Zn2+ into neurons suggests that this ion has the potential to act as a direct transmitter, by affecting postsynaptic signaling pathways. Taken overall, present studies are broadly supportive of a neuromodulatory role for Zn2+ at specific excitatory and inhibitory synapses.

9 October 2017 in Nature Structural & Molecular Biology
Verified
Journal Article
Closed access
PDF file
PMPaul Miller
Paul Miller
SSSuzanne Scott
Suzanne Scott
SMSimonas Masiulis
Simonas Masiulis
LCLuigi De Colibus
Luigi De Colibus
EPEls Pardon
Els Pardon
AAA Radu Aricescu
A Radu Aricescu